

# Sam Hollingworth

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4897828/publications.pdf>

Version: 2024-02-01

123  
papers

2,029  
citations

279798

23  
h-index

302126

39  
g-index

126  
all docs

126  
docs citations

126  
times ranked

3050  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clozapine use and prevalence in Australia 2016–2020. Australian and New Zealand Journal of Psychiatry, 2022, 56, 305-306.	2.3	4
2	Trends in Systemic Antifungal Use in Australia, 2005–2016: a Time-Series Analysis. Japanese Journal of Infectious Diseases, 2022, 75, 254-261.	1.2	2
3	Antibiotic use in Australian and Swedish primary care: a cross-country comparison. Scandinavian Journal of Primary Health Care, 2022, 40, 95-103.	1.5	3
4	The impact of COVID-19 on antidepressant sales and prescription dispensing in Australia. Australian and New Zealand Journal of Psychiatry, 2022, 56, 871-872.	2.3	3
5	Patient-based benefit-risk assessment of medicines: development, refinement, and validation of a content search strategy to retrieve relevant studies. Journal of the Medical Library Association: JMLA, 2022, 110, 185-204.	1.7	3
6	Patient concerns regarding antidepressant drug–drug interactions: a retrospective analysis using data from a medicines call centre. Journal of Primary Health Care, 2022, , .	0.6	1
7	Parity in female authorship in Australian pharmacoepidemiology research leveraging medicine dispensing data: How well are we doing?. Pharmacoepidemiology and Drug Safety, 2022, 31, 1010-1012.	1.9	1
8	Estimation of cardiac QTc intervals in people prescribed antipsychotics: a comparison of correction factors. Therapeutic Advances in Psychopharmacology, 2022, 12, 204512532211049.	2.7	4
9	Duration of opioid use and association with socioeconomic status, daily dose and formulation: a two-decade population study in Queensland, Australia. International Journal of Clinical Pharmacy, 2021, 43, 340-350.	2.1	10
10	Antidepressant use in Australia and Sweden—A cross-country comparison. Pharmacoepidemiology and Drug Safety, 2021, 30, 409-417.	1.9	19
11	Pharmaceutical opioids utilisation by dose, formulation, and socioeconomic status in Queensland, Australia: a population study over 22 years. International Journal of Clinical Pharmacy, 2021, 43, 328-339.	2.1	6
12	Research governance authorisation: the next frontier. Australian Health Review, 2021, 45, 389-392.	1.1	4
13	Metformin reduces 12-month change in body weight among people newly commenced on clozapine: a retrospective naturalistic cohort study. Therapeutic Advances in Psychopharmacology, 2021, 11, 204512532110006.	2.7	4
14	Does Switching Antipsychotics Ameliorate Weight Gain in Patients With Severe Mental Illness? A Systematic Review and Meta-analysis. Schizophrenia Bulletin, 2021, 47, 948-958.	4.3	26
15	Measuring Medicine Use: Applying ATC/DDD Methodology to Real-World Data. Pharmacy (Basel), 2021, 10, 1074-1081.	1.6	26
16	ICU Patients' Antibiotic Exposure and Triazole-Resistance in Invasive Candidiasis: Parallel Analysis of Aggregated and Individual Data. Frontiers in Pharmacology, 2021, 12, 586893.	3.5	1
17	Trends in Australian dental prescribing of antibiotics: 2005–2016. Australian Dental Journal, 2021, 66 Suppl 1, S37-S41.	1.5	4
18	Survival of advanced melanoma patients treated with immunotherapy and targeted therapy: A real-world study. Pharmacoepidemiology and Drug Safety, 2021, 30, 1371-1379.	1.9	0

#	ARTICLE	IF	CITATIONS
19	Bazett's correction formula overestimates the corrected QT among patients with antipsychotic induced tachycardia. <i>Schizophrenia Research</i> , 2021, 231, 22-23.	2.0	3
20	Using Prescription and Wastewater Data to Estimate the Correction Factors of Atenolol, Carbamazepine, and Naproxen for Wastewater-Based Epidemiology Applications. <i>Environmental Science &amp; Technology</i> , 2021, 55, 7551-7560.	10.0	19
21	Disease modifying therapies for relapsing-remitting multiple sclerosis: Use and costs in Australia (1996-2019). <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102835.	2.0	5
22	Opioid medication prescribing in Queensland, 1997â€™2018: a population study. <i>Medical Journal of Australia</i> , 2021, 215, 137-138.	1.7	3
23	Health technology assessment in sub-Saharan Africa: a descriptive analysis and narrative synthesis. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 39.	1.5	16
24	Questioning the Accuracy and Interpretation of Dispensed Patterns of Dental Emergency Medicines. <i>International Dental Journal</i> , 2021, 71, 281-282.	2.6	0
25	Harnessing medicines data at low cost to deliver better and safer care. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1621-1623.	1.9	0
26	Time to rethink our approach to the Pharmaceutical Benefits Scheme (PBS) listing of medicines: the case of pregabalin. <i>Australian Health Review</i> , 2021, 45, 261.	1.1	0
27	Community-based integrated care versus hospital outpatient care for managing patients with complex type 2 diabetes: costing analysis. <i>Australian Health Review</i> , 2021, 45, 42.	1.1	7
28	Long term impact of the WHI studies on information-seeking and decision-making in menopause symptoms management: a longitudinal analysis of questions to a medicines call centre. <i>BMC Women's Health</i> , 2021, 21, 348.	2.0	6
29	Consumption of medicines used for gastric acid-related disorders in Australia and South Korea: a cross-country comparison. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 547-555.	1.9	8
30	Implementing health technology assessment in Ghana to support universal health coverage: building relationships that focus on people, policy, and process. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 8-11.	0.5	21
31	Multiple opioid prescribers: A genuine quest for treatment rather than aberrant behaviour. A two-decade population-based study. <i>Addictive Behaviors</i> , 2020, 108, 106458.	3.0	9
32	Bortezomib use and outcomes for the treatment of multiple myeloma. <i>Internal Medicine Journal</i> , 2020, 50, 1059-1066.	0.8	6
33	Real-world questions and concerns about disease-modifying antirheumatic drugs (DMARDs): a retrospective analysis of questions to a medicine call center. <i>BMC Rheumatology</i> , 2020, 4, 27.	1.6	3
34	Health technology assessment and priority setting for universal health coverage: a qualitative study of stakeholdersâ€™ capacity, needs, policy areas of demand and perspectives in Nigeria. <i>Globalization and Health</i> , 2020, 16, 58.	4.9	20
35	Withdrawal and Misuse Concerns of Consumers regarding Opioid Analgesic and Anxiolytic, Hypnotic and Sedative Medicines. <i>Substance Use and Misuse</i> , 2020, 55, 1980-1992.	1.4	0
36	What do we need to know? Data sources to support evidence-based decisions using health technology assessment in Ghana. <i>Health Research Policy and Systems</i> , 2020, 18, 41.	2.8	9

#	ARTICLE	IF	CITATIONS
37	Dental opioid prescribing rates after the up-scheduling of codeine in Australia. <i>Scientific Reports</i> , 2020, 10, 8463.	3.3	15
38	Health technology assessment capacity at national level in sub-Saharan Africa: an initial survey of stakeholders. <i>F1000Research</i> , 2020, 9, 364.	1.6	8
39	Does consumer medicines interest reflect medicines use? An observational study comparing medicines call center queries with medicines use. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 440-447.	3.0	4
40	Antifungal agents for invasive candidiasis in non-neutropenic critically ill adults: What do the guidelines recommend?. <i>International Journal of Infectious Diseases</i> , 2019, 89, 137-145.	3.3	11
41	Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 1149-1160.	2.4	38
42	Why aren't Australian pharmacists supplying naloxone? Findings from a qualitative study. <i>International Journal of Drug Policy</i> , 2019, 69, 46-52.	3.3	23
43	Longitudinal impact of the Women's Health Initiative study on hormone therapy use in Australia. <i>Climacteric</i> , 2019, 22, 489-497.	2.4	8
44	Response to Comment on Johnson et al. Cost-effectiveness Analysis of Routine Screening Using Massively Parallel Sequencing for Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Cohort: Reduced Health System Costs and Improved Patient Quality of Life. <i>Diabetes Care</i> 2019;42:69-76. <i>Diabetes Care</i> , 2019, 42, e79-e80.	8.6	0
45	How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 1014-1020.	3.0	13
46	Availability, Price, and Affordability of Essential Medicines to Manage Noncommunicable Diseases: A National Survey From Nepal. <i>Inquiry (United States)</i> , 2019, 56, 004695801988757.	0.9	11
47	Medicine use during acute and chronic postinjury periods in whiplash-injured individuals. <i>Pain</i> , 2019, 160, 844-851.	4.2	5
48	Forecasting the amount and cost of medicine to treat type 2 diabetes mellitus in Nepal using knowledge on medicine usage from a developed country. <i>Journal of Pharmaceutical Health Services Research</i> , 2019, 10, 91-99.	0.6	2
49	Cost-effectiveness Analysis of Routine Screening Using Massively Parallel Sequencing for Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Cohort: Reduced Health System Costs and Improved Patient Quality of Life. <i>Diabetes Care</i> , 2019, 42, 69-76.	8.6	24
50	Prescribed Dose of Opioids and Overdose: A Systematic Review and Meta-Analysis of Unintentional Prescription Opioid Overdose. <i>CNS Drugs</i> , 2018, 32, 101-116.	5.9	50
51	Patterns in use and costs of subsidising 5-aminosalicylic acid compounds and biologic agents in the treatment of inflammatory bowel disease in Australia. <i>Digestive and Liver Disease</i> , 2018, 50, 314-317.	0.9	0
52	More needs to be spent on hepatitis C treatment, not less. <i>Internal Medicine Journal</i> , 2018, 48, 364-366.	0.8	0
53	Clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993-2014. <i>Psychopharmacology</i> , 2018, 235, 1915-1921.	3.1	17
54	A Review of Medication Use as an Indicator of Human Health Impact in Environmentally Stressed Areas. <i>Annals of Global Health</i> , 2018, 82, 111.	2.0	4

#	ARTICLE	IF	CITATIONS
55	Use of complementary and alternative medicines in people with depression and central obesity: Findings from a Tai Chi and Qigong study. <i>Journal of Traditional Chinese Medical Sciences</i> , 2018, 5, 100-109.	0.2	1
56	Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: <scp>A</scp> randomized controlled trial (<scp>CODEX</scp>). <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1050-1055.	4.4	49
57	The bidirectional relationship between vasomotor symptoms and depression across the menopausal transition: a systematic review of longitudinal studies. <i>Menopause</i> , 2018, 25, 109-120.	2.0	32
58	Prescription Opioid Fatalities: Examining Why the Healer Could be the Culprit. <i>Drug Safety</i> , 2018, 41, 1023-1033.	3.2	8
59	Survival outcomes in patients with non-small-cell lung cancer treated with erlotinib. <i>Anti-Cancer Drugs</i> , 2018, 29, 786-790.	1.4	1
60	Cost saving with a GP-led integrated health service delivery model for complex chronic disease: an optimal Beacon practice. <i>International Journal of Integrated Care</i> , 2018, 18, 25.	0.2	0
61	Under-reporting of socio-economic status in randomized control trials of biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, kew460.	1.9	0
62	â€Repeatâ€™ prescriptions and antibiotic resistance: findings from Australian community pharmacy. <i>International Journal of Pharmacy Practice</i> , 2017, 25, 50-58.	0.6	5
63	Prescribing patterns of dental practitioners in Australia from 2001 to 2012. <i>Antimicrobials. Australian Dental Journal</i> , 2017, 62, 52-57.	1.5	38
64	Triptan use in Australia 1997-2015: A pharmacoepidemiological study. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 155-159.	2.1	3
65	The impact of clozapine on hospital use: a systematic review and meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , 2017, 135, 296-309.	4.5	90
66	Prescribing patterns of analgesics and other medicines by dental practitioners in Australia from 2001 to 2012. <i>Community Dentistry and Oral Epidemiology</i> , 2017, 45, 303-309.	1.9	25
67	International trends in clozapine use: a study in 17 countries. <i>Acta Psychiatrica Scandinavica</i> , 2017, 136, 37-51.	4.5	188
68	Impact of a general practitioner-led integrated model of care on the cost of potentially preventable diabetes-related hospitalisations. <i>Primary Care Diabetes</i> , 2017, 11, 344-347.	1.8	9
69	Ezetimibe: Use, costs, and adverse events in Australia. <i>Cardiovascular Therapeutics</i> , 2017, 35, 40-46.	2.5	12
70	Opioid analgesic use in Australia and The Netherlands: a cross-country comparison. <i>International Journal of Clinical Pharmacy</i> , 2017, 39, 874-880.	2.1	21
71	Effectiveness of bevacizumab and cetuximab in metastatic colorectal cancer across selected public hospitals in Queensland. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e253-e261.	1.1	4
72	Forecasting the quantity and cost of medicines to treat non-communicable diseases in low- and middle-income countries: Applying knowledge on medicine use from developed countries. <i>Research in Social and Administrative Pharmacy</i> , 2017, 13, 257-258.	3.0	1

#	ARTICLE	IF	CITATIONS
73	Associations of Guideline Recommended Medications for Acute Coronary Syndromes With Fall-Related Hospitalizations and Cardiovascular Events in Older Women With Ischemic Heart Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, 259-265.	3.6	14
74	Use of Healthcare Services by Patients with Non-Communicable Diseases in Nepal: A Qualitative Study with Healthcare Providers. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2017, 11, LC01-LC05.	0.8	6
75	Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting. <i>International Journal of Clinical Pharmacy</i> , 2017, 39, 836-843.	2.1	4
76	Patterns in use and costs of conventional and biologic disease-modifying anti-rheumatic drugs in Australia. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 907-912.	0.8	4
77	Understanding quality use of medicines in refugee communities in Australian primary care: a qualitative study. <i>British Journal of General Practice</i> , 2016, 66, e397-e409.	1.4	20
78	Knowledge and attitudes of final year pharmacy students toward opioid substitution therapy. <i>Journal of Pharmacy Practice and Research</i> , 2016, 46, 216-221.	0.8	0
79	Off-label use of tumour necrosis factor- $\alpha$ inhibitors and anakinra at an Australian tertiary hospital. <i>Internal Medicine Journal</i> , 2016, 46, 1386-1391.	0.8	2
80	Case conference primary-secondary care planning at end of life can reduce the cost of hospitalisations. <i>BMC Palliative Care</i> , 2016, 15, 84.	1.8	14
81	Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes. <i>Journal of Psychopharmacology</i> , 2016, 30, 227-236.	4.0	37
82	Pharmacy workforce to prevent and manage non-communicable diseases in developing nations: The case of Nepal. <i>Research in Social and Administrative Pharmacy</i> , 2016, 12, 655-659.	3.0	10
83	Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial. <i>BJPsych Open</i> , 2015, 1, 67-73.	0.7	12
84	Opioid analgesic prescribing in Australia: a focus on gender and age. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 628-636.	1.9	34
85	Clozapine in the community: Improved access or risky free-for-all?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 863-865.	2.3	4
86	Shift in disease burden from communicable to non-communicable diseases: aiming to achieve Universal Health Coverage in Nepal. <i>Perspectives in Public Health</i> , 2015, 135, 177-178.	1.6	2
87	Clozapine-induced myocarditis: Separating the wheat from the chaff. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 188-188.	2.3	19
88	Effects of decentralisation and health system reform on health workforce and quality of care in Indonesia, 1993-2007. <i>International Journal of Health Planning and Management</i> , 2015, 30, E16-30.	1.7	8
89	Consumer knowledge and perceptions about antibiotics and upper respiratory tract infections in a community pharmacy. <i>International Journal of Clinical Pharmacy</i> , 2015, 37, 1213-1221.	2.1	23
90	Increasing Clozapine Dispensing Trends in Queensland, Australia 2004-2013. <i>Pharmacopsychiatry</i> , 2015, 48, 164-169.	3.3	29

#	ARTICLE	IF	CITATIONS
91	Dopamine Agonists: Time Pattern of Adverse Effects Reporting in Australia. <i>Drugs - Real World Outcomes</i> , 2015, 2, 199-203.	1.6	6
92	Multiple sclerosis disease modifying medicine utilisation in Australia. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 2083-2087.	1.5	5
93	A new model of integrated primary-secondary care for complex diabetes in the community: study protocol for a randomised controlled trial. <i>Trials</i> , 2013, 14, 382.	1.6	14
94	Quality of physical resources of health facilities in Indonesia: a panel study 1993-2007. <i>International Journal for Quality in Health Care</i> , 2013, 25, 488-496.	1.8	6
95	National trends in the community prescribing of second-generation antipsychotic medications in Australian children and youth: the incomplete story. <i>Australasian Psychiatry</i> , 2013, 21, 442-445.	0.7	8
96	Pharmacoepidemiology and the Australian regional prevalence of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1712-1716.	3.0	9
97	Prescribing databases can be used to monitor trends in opioid analgesic prescribing in Australia. <i>Australian and New Zealand Journal of Public Health</i> , 2013, 37, 132-138.	1.8	23
98	The prescribing of antiepileptic drugs for pregnant Australian women. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2012, 52, 49-53.	1.0	24
99	Prescribing trends in cognition enhancing drugs in Australia. <i>International Psychogeriatrics</i> , 2011, 23, 238-245.	1.0	13
100	Utilization of anti-Parkinson drugs in Australia: 1995-2009. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 450-456.	1.9	16
101	Australian National Trends in Stimulant Dispensing: 2002-2009. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 332-336.	2.3	32
102	Psychiatric Drug Prescribing in Elderly Australians: Time for Action. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 705-708.	2.3	11
103	Antiepileptic drugs in Australia: 2002-2007. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 82-89.	1.9	46
104	Anxiolytic, hypnotic and sedative medication use in Australia. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 280-288.	1.9	74
105	Marked increase in proton pump inhibitors use in Australia. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 1019-1024.	1.9	101
106	Changing patterns of antiepileptic drug use in pregnant Australian women. <i>Acta Neurologica Scandinavica</i> , 2010, 121, 89-93.	2.1	59
107	Patterns of Antipsychotic Medication Use in Australia 2002-2007. <i>Australian and New Zealand Journal of Psychiatry</i> , 2010, 44, 372-377.	2.3	83
108	PHP34 THE EVALUATION OF HEALTH-CARE SYSTEMS OF CHINA, HONG KONG, VIETNAM, THAILAND, MALAYSIA, SINGAPORE AND AUSTRALIA. <i>Value in Health</i> , 2010, 13, A538.	0.3	0

#	ARTICLE	IF	CITATIONS
109	Secondary Prevention of Osteoporosis in Australia. <i>Drugs and Aging</i> , 2010, 27, 255-264.	2.7	11
110	Affective and anxiety disorders: prevalence, treatment and antidepressant medication use. <i>Australian and New Zealand Journal of Psychiatry</i> , 2010, 44, 513-9.	2.3	62
111	Sociodemographic correlates of antidepressant utilisation in Australia. <i>Medical Journal of Australia</i> , 2009, 190, 479-483.	1.7	33
112	In Australia are people born in other countries at higher risk of road trauma than locally born people?. <i>Accident Analysis and Prevention</i> , 2004, 36, 375-381.	5.7	16
113	Rebound increase in fetal breathing movements after 24-h prostaglandin E2 infusion in fetal sheep. <i>Journal of Applied Physiology</i> , 1996, 80, 166-175.	2.5	5
114	Continuous intrafetal infusion of prostaglandin E2 prematurely activates the hypothalamo-pituitary-adrenal axis and induces parturition in sheep.. <i>Endocrinology</i> , 1996, 137, 2424-2431.	2.8	34
115	Continuous intrafetal infusion of prostaglandin E2 prematurely activates the hypothalamo-pituitary-adrenal axis and induces parturition in sheep. <i>Endocrinology</i> , 1996, 137, 2424-2431.	2.8	4
116	Prostaglandin E2 administered to fetal sheep increases the plasma concentration of adrenocorticotropin (ACTH) and the proportion of ACTH in low molecular weight forms.. <i>Endocrinology</i> , 1995, 136, 1233-1240.	2.8	31
117	Prostaglandin E2 administered to fetal sheep increases the plasma concentration of adrenocorticotropin (ACTH) and the proportion of ACTH in low molecular weight forms. <i>Endocrinology</i> , 1995, 136, 1233-1240.	2.8	8
118	Effect of Late Hypothalamo-Pituitary Disconnection on the Development of the HPA Axis in the Ovine Fetus and the Initiation of Parturition. <i>Journal of Neuroendocrinology</i> , 1994, 6, 25-31.	2.6	29
119	Chronic administration of low doses of adrenocorticotropin to hypophysectomized fetal sheep leads to normal term labor. <i>Endocrinology</i> , 1994, 134, 1389-1394.	2.8	5
120	The trigger for parturition in sheep: fetal hypothalamus or placenta?. <i>Journal of Developmental Physiology</i> , 1991, 15, 71-9.	0.3	27
121	Prostaglandin G/H synthase activity in ovine cotyledons: a gestational profile. <i>Eicosanoids</i> , 1990, 3, 231-6.	0.7	15
122	The metabolism and excretion of oestradiol-3 <sup>12</sup> -d-glucuronide in rats. <i>Comparative Biochemistry and Physiology Part B: Comparative Biochemistry</i> , 1988, 90, 99-101.	0.2	0
123	Health technology assessment capacity at national level in sub-Saharan Africa: an initial survey of stakeholders. <i>F1000Research</i> , 0, 9, 364.	1.6	0